Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children
Authors:
- Djeneba B. FofanaDFDjeneba B. Fofana
- Houdou DiarraHDHoudou Diarra
- Ibrahima GuindoIGIbrahima Guindo
- Mahamadou K. SavadogoMSMahamadou K. Savadogo
- Marceline D’almeidaMDMarceline D’almeida
- Fatoumata I. DialloFDFatoumata I. Diallo
- Aliou BaldéABAliou Baldé
- Cathia SouliéCSCathia Soulié
- Amadou KoneAKAmadou Kone
- Anne-Geneviève MarcelinAMAnne-Geneviève Marcelin
- Almoustapha I. MaigaAMAlmoustapha I. Maiga
- Sidonie Lambert-NiclotSLSidonie Lambert-Niclot
Open Access
Abstract
Integrase inhibitors (INIs) are a potent option for HIV treatment. Limited data exist on INI resistance in West Africa, particularly in children living with HIV/AIDS. We determined the prevalence of integrase gene polymorphisms and the frequency of naturally occurring amino acid (aa) substitutions at positions associated with INI resistance. Dried blood spot (DBS) samples were obtained from one hundred and seven (107) HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali. All children were naïve to INI treatment, 56 were naïve to anti-retroviral therapy (ART), and 51 had received ART. Genetic sequencing of HIV integrase was successful in 75 samples. The aa changes at integrase positions associated with INI resistance were examined according to the Stanford HIV Genotypic Resistance database. The median ages were 2.6 and 10 years for ART-naïve and -treated children, respectively. The most common subtypes observed were CRF02_AG (74.7%) followed by CRF06_cpx (20%). No major INI-resistance mutations at positions 66, 92, 121, 143, 147, 148, 155, and 263 were detected. The most prevalent INI accessory resistance mutations were: L74I/M (14/75, 18.6%) followed by E157Q (8/75, 10.6%), G163E/N/T/Q (5/75, 6.6%), Q95A/H/P (2/75, 2.6%), and T97A (4/75, 5.3%). Other substitutions observed were M50I/L/P, H51E/P/S/Q, I72V, T112V, V201I, and T206S. Polymorphisms at positions which may influence the genetic barrier and/or drive the selection of specific INI-resistance pathways were detected. However, no transmitted drug resistance (TDR) to INI was detected among samples of INI-naïve patients. These findings support the use of this treatment class for children with HIV-1, particularly in West Africa.Keywords
Funding Information
- Fogarty International Center (K43TW011957, ANRS-MIE22295)
- Agence Nationale de la Recherche sur le SIDA et les Maladies Infectieuses Emergentes (ANRS MIE) (K43TW011957, ANRS-MIE22295)
This publication has 43 references indexed in Scilit:
- Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 VariantsHIV Research & Clinical Practice, 2013
- Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- Development of Antiretroviral Drug ResistanceNew England Journal of Medicine, 2011
- HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with RaltegravirAIDS Research and Human Retroviruses, 2010
- Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitorsJournal of Antimicrobial Chemotherapy, 2010
- Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infectionJournal of Antimicrobial Chemotherapy, 2009
- Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase InhibitorsAntimicrobial Agents and Chemotherapy, 2009
- Evolution of raltegravir resistance during therapyJournal of Antimicrobial Chemotherapy, 2009
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008